Roles of NAD+ in Health and Aging

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

NAD+, the essential metabolite involved in multiple reactions such as the regulation of cellular metabolism, energy production, DNA repair, mitophagy and autophagy, inflammation, and neuronal function, has been the subject of intense research in the field of aging and disease over the last decade. NAD+ levels decline with aging and in some age-related diseases, and reduction in NAD+ affects all the hallmarks of aging. Here, we present an overview of the discovery of NAD+, the cellular pathways of producing and consuming NAD+, and discuss how imbalances in the production rate and cellular request of NAD+ likely contribute to aging and age-related diseases including neurodegeneration. Preclinical studies have revealed great potential for NAD+ precursors in promotion of healthy aging and improvement of neurodegeneration. This has led to the initiation of several clinical trials with NAD+ precursors to treat accelerated aging, age-associated dysfunctions, and diseases including Alzheimer's and Parkinson's. NAD supplementation has great future potential clinically, and these studies will also provide insight into the mechanisms of aging.
OriginalsprogEngelsk
Artikelnummera041193
TidsskriftCold Spring Harbor Perspectives in Medicine
Vol/bind14
Udgave nummer1
Antal sider27
ISSN2157-1422
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
The authors acknowledge the valuable work of the many investigators whose published articles they were unable to cite owing to space limitations. E.F.F. is supported by Cure Alzheimer’s Fund (#282952), HELSE SØR-ØST (#2020001, #2021021, #2023093), the Research Council of Norway (#262175, #334361), Molecule AG/VI-TADAO (#282942), NordForsk Foundation (#119986), the National Natural Science Foundation of China (#81971327), Akershus University Hospital (#269901, #261973, #262960), the Civi-tan Norges Forskningsfond for Alzheimers syk-dom (#281931), the Czech Republic-Norway KAPPA programme (with Martin Vyhnálek, #TO01000215), and the Rosa Sløyfe/Norwegian Cancer Society & Norwegian Breast Cancer Society (#207819). S.L. has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skło-dowska-Curie grant agreement No. 801133. Y.H. was supported by the National Natural Science Foundation of China (#82171405), and the Lingang Laboratory (#LG-QS-202205-10). The figures were generated using the subscribed software BioRender. V.A.B. is supported by the intramural program of the National Institute on Aging, National Institutes of Health (NIH), USA.

Publisher Copyright:
© 2024 Cold Spring Harbor Laboratory Press; all rights reserved;.

ID: 380149837